Quantum Biopharma (QNTM) Long-Term Debt Issuances (2024 - 2026)

Quantum Biopharma has disclosed Long-Term Debt Issuances across 3 years of filings, most recently posting $2.7 million for Q1 2026.

• Long-Term Debt Issuances for Q1 2026 came in at $2.7 million, up 2.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (down 26.79% YoY), and the FY2025 annual result was $2.1 million, up 583.64% from the prior year.
• Long-Term Debt Issuances came in at $2.7 million for Q1 2026 at Quantum Biopharma, up from -$31372.0 in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $2.7 million in Q1 2026 to a low of -$556954.0 in Q2 2025.
• The 3-year median for Long-Term Debt Issuances is $168554.5 (2024), against an average of $644454.1.
• Peak annual rise in Long-Term Debt Issuances reached 111.33% in 2025, while the deepest fall reached 283.93% in 2025.
• Quantum Biopharma's Long-Term Debt Issuances stood at $309138.0 in 2024, then slumped by 110.15% to -$31372.0 in 2025, then surged by 8811.94% to $2.7 million in 2026.
• The last three Long-Term Debt Issuances figures came in at $2.7 million (Q1 2026), -$31372.0 (Q4 2025), and $34308.0 (Q3 2025), per Business Quant data.